Abstract
Fungi have long been implicated as important pathogens in selected patients with acute or chronic sinusitis. Inhalation of fungal spores is considered to be the primary means by which these organisms gain access to the sinonasal tract. Fungal sinusitis is an important clinical entity. However, changing terminology and emerging theories of pathogenesis make it an area of confusion and controversy. An analysis of tissue invasion and host immunological response is an important step in the evaluation of the patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Demuri GP, Wald ER. Sinusitis. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 842.
Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.
Kontoyiannis DP, Lewis RE. Agents of mucormycosis and entomophthoromycosis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 3257–67.
Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.
Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11(4):301–11.
Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47:226–35.
Spellberg B, Ibrahim AS, et al. Mucormycosis. In: Longo DL, editor. Harrison’s principles of internal medicine. 18th ed. London: The McGraw-Hill Companies, Inc.; 2012. p. 1663–6.
Thompson 3rd GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170:291–313.
John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005;11(7):515–7.
Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am. 2008;26(2):571–95.
Neuman TS, Thom SR, editors. Physiology and rationale of hyperbaric oxygen therapy. Philadelphia: Saunders Elsevier; 2008. pp 321–47.
Soman R, Gupta N, Shetty A, Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. J Antimicrob Chemother. 2012;67(3):783–4.
Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother. 2010;54:484–90.
Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007; 7:358–68.
Ashdown B, Tien R, Felsberg G. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol. 1994;162:155–9.
Patterson TF. Aspergillus species. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 3241–55.
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46:327–60.
Chaudhary AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res. 2008;127:521–30.
Cox GM, Perfect JR. Fungal rhinosinusitis. [homepage on the Internet]. 2012 [cited 25 Feb 2013]. Available from: http://www.uptodate.com.
De Carpentier JE, Ramamurthy L, Denning DW, Taylor PH. An algorithmic approach to aspergillus sinusitis. J Laryngol Otol. 1994;108:314–8.
Zaas A. Fusarium, Scedosporium [homepage on the internet]. 2012 [cited 25 Feb 2013]. Available from: http://www.hopkinsguides.com.
Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mold infections. Med Mycol. 2008;46(1):23–9.
Moussett S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84(11):734–41.
Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460–6.
Chamilos G, Lewis RE, Kontoyiannis DP. Delaying Amphotericin B- based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.
Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mold related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(1):i5–14.
Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-rhizopus, mucor and lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer India
About this chapter
Cite this chapter
Soman, R., Sunavala, A. (2014). Management of Invasive Fungal Sinusitis. In: Mankekar, G. (eds) Invasive Fungal Rhinosinusitis. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1530-1_8
Download citation
DOI: https://doi.org/10.1007/978-81-322-1530-1_8
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-1529-5
Online ISBN: 978-81-322-1530-1
eBook Packages: MedicineMedicine (R0)